How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales
LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. Despite these challenges, the company reinforced its growth narrative, though the revised guidance highlights …